US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. July 21, 2022

    SF, Walgreens Continue Opioid Bellwether Battle Post-Trial

    In post-trial filings Wednesday, San Francisco argued Walgreens' failure to prevent the diversion of "dangerous and highly addictive" opioids it distributed and dispensed "substantially contributed" to the city's opioid crisis, while the pharmacy giant held firm that the case lacked evidence of any harm by an opioid it sold.

  2. July 19, 2022

    Top Product Liability Cases Of 2022: Midyear Review

    Major product liability cases so far in 2022 include a ruling in West Virginia against local governments seeking relief from drug distributors for the opioid crisis and a historic settlement with gunmaker Remington to end claims brought by the families of Sandy Hook victims. Here, Law360 looks at key cases from the first half of the year.

  3. July 19, 2022

    J&J Wants Opioid Claims From NY Towns, Cities Tossed

    Johnson & Johnson wants an Ohio federal court to toss opioid claims made against the company by a host of New York municipalities, saying a change to an Empire State law bars those allegations.

  4. July 13, 2022

    Rite Aid Quietly Inks Opioid MDL Deals, Litigation Freeze

    Rite Aid Corp. has struck deals worth $10.5 million to exit three opioid-crisis cases hurtling toward bellwether trials in multidistrict litigation and to shield the pharmacy chain for 18 months from any other test cases in the MDL, according to plaintiffs counsel and an agreement marked confidential.

  5. July 13, 2022

    Walgreens Says SF Opioid Case Has 'Fatal Flaw' As Trial Ends

    Left as the lone defendant in a bellwether bench trial brought by San Francisco over the city's opioid crisis, Walgreens argued during its closing arguments Wednesday that the city didn't show any evidence its pharmacists dispensed medically inappropriate drugs — a "fatal flaw" in the case against it.

  6. July 12, 2022

    $58M Opioid Deal Cuts Allergan, Teva From SF Bellwether Trial

    San Francisco struck settlements worth almost $58 million with Allergan and Teva Pharmaceuticals on Tuesday in the sole ongoing trial over the pharmaceutical industry's role in a nationwide crisis of opioid abuse, leaving Walgreens as the last company in the closely watched showdown.

  7. July 08, 2022

    W.Va. Opioid Verdict Widens Judge-Jury Split On Vital Theory

    A resounding victory by drug distributors in a bench trial over West Virginia's catastrophic opioid crisis underscores a growing gulf between judges and juries in broader opioid litigation, with judges increasingly rejecting a crucial legal theory while juries embrace it.

  8. June 30, 2022

    SF Says Pharmaceutical Cos. Created City's Opioid Crisis

    A lawyer for San Francisco has told a California federal judge overseeing a bellwether bench trial in multidistrict opioid litigation that Anda, Allergan, Teva and Walgreens promoted and distributed the powerful painkillers in ways that created a public nuisance that endangered the health and safety of the city's residents.

  9. June 27, 2022

    As Opioid Trial Ends, Judge Jokes Of 'Generous' Time Limits

    A San Francisco federal judge who put strict time limits on a bellwether bench trial in multidistrict opioid litigation noted Monday that both sides wrapped up their cases within their allotted 45 hours, prompting him to wonder to courtroom chuckles if he "was just too generous."

  10. June 16, 2022

    Yale Law Prof Defends Allergan In SF Opioid Trial

    A Yale University law professor — the final live defense witness in a bellwether opioid bench trial in San Francisco — testified Thursday that Allergan entities were not responsible for the conduct of Alpharma, a company that had owned a branded opioid called Kadian that Allergan later acquired.